Pharmacy benefit managers and health carriers required to include lower-cost drugs in their formularies, and formulary structure and formulary tiering for each health plan required to give preference to the drug with the lowest out-of-pocket cost to the patient.
HF1076 would require pharmacy benefit managers and health carriers to include lower-cost alternatives in their formularies when they cover a brand-name drug, generic drug, brand-name biologic, or biosimilar. The bill is designed to ensure that if a cheaper equivalent option exists—measured by wholesale acquisition cost—it must be listed on the formulary, including newly approved generics and biosimilars that are less expensive than the lowest-cost equivalent already covered.
The bill also directs health plans to structure formulary tiers to favor the drug product with the lowest out-of-pocket cost for the patient. It prohibits prior authorization, step therapy, or other coverage restrictions that would make it harder to access the lowest-cost option, and it bars pharmacy restrictions that would impede access to that drug. The proposal would take effect January 1, 2026.
If enacted, HF1076 would add a new section to Minnesota Statutes chapter 62W and impose new formulary and tiering requirements on pharmacy benefit managers and health carriers. It would affect how health plans design prescription drug coverage, requiring them to include and prefer lower-cost equivalents and to remove utilization-management barriers for the least expensive covered option. The practical impact would be on insurers, PBMs, pharmacies, and patients seeking access to lower-cost prescription drugs, including generics and biosimilars.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears to be consumer- and cost-savings oriented. The bill is framed as a measure to improve affordability and access by steering coverage toward cheaper equivalent drugs and reducing administrative barriers. No opposing arguments or recorded vote history are available in the provided context.
The main policy tension in HF1076 is between lowering patient out-of-pocket costs and limiting the discretion of pharmacy benefit managers and health carriers to manage formularies and utilization. Supporters would likely emphasize affordability, transparency, and faster access to generics and biosimilars, while potential critics may argue that mandatory formulary inclusion and restrictions on prior authorization or step therapy could reduce plan flexibility, affect negotiated rebates, or interfere with formulary management. No specific stakeholder positions are included in the provided committee materials.